References
- 1. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for induction of remission of Crohn’s disease. Cohrane Database System Rev.2, CDOOO545.
- 2. Smith M, Blacker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract. 2013; 67(2): 161-9.
- 3. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
- 4. D’Halluin PN, Tribut O, Branger B, et al. RBC 6-TGN and hematological parameters in patients with Crohn’s disease treated by azathioprine. Gastroenterol Clin Biol. 2005; 29: 1264-9.16518285
- 5. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut. 2011; 48: 642-6.
- 6. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subject as amended. Helsinki. 2013.
- 7. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005; 37: 282-97.
- 8. Saibeni S, Virgilio T, D’Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008; 40(10): 814–20.
- 9. McLean L, Cross R. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014; 8(3): 223-40.
- 10. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow up study of 3931 patients. Inflamm Bowel Dis.2013; 19(7): 1404-10.
- 11. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16: 1743-50.
- 12. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised iniciation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55: 1423-31.
- 13. Lee MN, Kang B, Choi SY, et al. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 2015; 21(5): 1054-62.
- 14. Zhang B, Xu X, Zeng X, et al. Correlation of Thiopurine Methyltransferase Activity and 6- Thioguanine Nucleotide Concentration in Han Chinese Patients treated with Azathioprine 25 to 100mg: A 1-Year Single-Center, Prospective study. Cur Ther Research. 2006; 67(4): 270-82.
- 15. Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Inter Med J. 2005; 35(10): 580-5.
- 16. Cohen R. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: “Partly cloudy”. Gastroenterol 2002; 122: 2082-84.
- 17. Lowry PW, Franklin CL, Weaver AL, et al. Leukopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001; 49: 656-64.
- 18. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease; a 30 year review. Gut. 2002; 50: 485-9.10.1136/gut.50.4.485